Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Contrast Enhancement in Magnetic Resonance Imaging Clear all
Completed No phase listed Observational

Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer

NCT00071357
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 6:21 AM EDT
Terminated Phase 2 Interventional Results available

Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction

NCT01440517
View directory record Official record
Conditions
Diabetes Mellitus, Heart Failure
Interventions
Tc99m-Maraciclatide
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy

NCT00610493
View directory record Official record
Conditions
Advanced Cancer
Interventions
Bevacizumab, Temsirolimus, Additional Blood Drawn, Biopsy, DCE-MRI Scan
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Phase 2 Interventional

Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer

NCT00043017
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI/MRS, gadopentetate dimeglumine
Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 4, 2026, 6:21 AM EDT
Completed No phase listed Observational

Digital Breast Tomosynthesis Versus Contrast Enhanced Magnetic Resonance Imaging (MRI) for Breast Cancer Staging

NCT01060085
View directory record Official record
Conditions
Ductal Carcinoma In Situ, Invasive Breast Cancer
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
30 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

NCT01012674
View directory record Official record
Conditions
Cerebral Arterial Diseases
Interventions
Dotarem, TOF MRA
Drug · Other
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)

NCT00908310
View directory record Official record
Conditions
Chronic Kidney Disease, Renal Insufficiency
Interventions
Omniscan
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 4, 2026, 6:21 AM EDT
Completed No phase listed Observational

Magnetic Resonance Angiography (MRA) for the Diagnosis of Atherosclerosis

NCT00001841
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Phase 1 Interventional Results available

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

NCT01544166
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadobutrol (Gadavist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Savannah, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 4, 2026, 6:21 AM EDT
Terminated Early Phase 1 Interventional

Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI

NCT01895829
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Magnetic Resonance Imaging (MRI), Ferumoxytol
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Phase 3 Interventional

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

NCT05915702
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Indian Wells, California • Orange, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Not applicable Interventional

Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection

NCT01575951
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
MRI-DCE
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 4, 2026, 6:21 AM EDT
Recruiting Not applicable Interventional

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body

NCT03145077
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 4, 2026, 6:21 AM EDT
Terminated Early Phase 1 Interventional

Comparison of CE-DBT and MRI in Patients With Known Breast Lesions

NCT05754749
View directory record Official record
Conditions
Breast Cancer
Interventions
Iohexol 350 Mg/mL Injectable Solution
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 4, 2026, 6:21 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

NCT07472491
View directory record Official record
Conditions
Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
Interventions
Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol
Drug · Diagnostic Test
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

NCT01104584
View directory record Official record
Conditions
Breast Cancer
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Tucson, Arizona • Oakland, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2014 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Phase 4 Interventional

DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function

NCT00401687
View directory record Official record
Conditions
Ventricular Ejection Fraction
Interventions
Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Chicago, Illinois • Washington DC, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 20, 2011 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

Comparison of Magnetic Resonance Angiography and Standard Angiography in Diagnosing Atherosclerosis

NCT00001946
View directory record Official record
Conditions
Atherosclerosis
Interventions
Magnetic resonance angiography
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 6:21 AM EDT
Completed No phase listed Observational

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

NCT05350189
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging
Interventions
Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
1,602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 4, 2026, 6:21 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

DCE MRI in Patients With Pancreatic Cancer

NCT02070705
View directory record Official record
Conditions
Familial Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

NCT05915728
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 4, 2026, 6:21 AM EDT
Active, not recruiting Not applicable Interventional

MRI in Diagnosing Solid Tumors of the Eye and Orbit

NCT01653080
View directory record Official record
Conditions
Eye Cancer
Interventions
dynamic contrast-enhanced MRI
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 4, 2026, 6:21 AM EDT
Completed No phase listed Observational

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

NCT03910114
View directory record Official record
Conditions
Magnetic Resonance Imaging Contrast Agents
Interventions
Magnevist, Dotarem, Gadovist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
500 participants
Timeline
1990 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 4, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

NCT01010932
View directory record Official record
Conditions
Cerebral Arterial Diseases
Interventions
Dotarem, TOF MRA
Drug · Other
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 4, 2026, 6:21 AM EDT